Thus a replication-competent and IFN antagonism-negative PRRSV vaccine will improve the host anti-viral immune response including the innate immunity, CD4+ T cells, CTLs, and B cells, and provide effective protection not only from homologous infection but also from heterologous infection [41]. The gene discussed is IFNA1; the disease is infection.